×

Use of MVA to treat prostate cancer

  • US 8,377,688 B2
  • Filed: 08/30/2010
  • Issued: 02/19/2013
  • Est. Priority Date: 10/18/2007
  • Status: Expired due to Fees
First Claim
Patent Images

1. A recombinant modified vaccinia virus Ankara (MVA) expressing a polypeptide comprising a human prostatic acid phosphatase (PAP) antigen, wherein the recombinant MVA virus induces B-cell and T-cell immune responses against the human PAP antigen when administered to a human host.

View all claims
  • 2 Assignments
Timeline View
Assignment View
    ×
    ×